1
|
Blue TE. Description and Analysis of an Accelerator-Based Production Method of the Brachytherapy Source 145Sm. NUCL TECHNOL 2017. [DOI: 10.13182/nt88-a34131] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- Thomas E. Blue
- The Ohio State University Department of Mechanical Engineering Nuclear Engineering Program, Columbus, Ohio 43210
| |
Collapse
|
2
|
Bayart E, Pouzoulet F, Calmels L, Dadoun J, Allot F, Plagnard J, Ravanat JL, Bridier A, Denozière M, Bourhis J, Deutsch E. Enhancement of IUdR Radiosensitization by Low-Energy Photons Results from Increased and Persistent DNA Damage. PLoS One 2017; 12:e0168395. [PMID: 28045991 PMCID: PMC5207426 DOI: 10.1371/journal.pone.0168395] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2016] [Accepted: 11/29/2016] [Indexed: 01/10/2023] Open
Abstract
Low-energy X-rays induce Auger cascades by photoelectric absorption in iodine present in the DNA of cells labeled with 5-iodo-2’-deoxyuridine (IUdR). This photoactivation therapy results in enhanced cellular sensitivity to radiation which reaches its maximum with 50 keV photons. Synchrotron core facilities are the only way to generate such monochromatic beams. However, these structures are not adapted for the routine treatment of patients. In this study, we generated two beams emitting photon energy means of 42 and 50 keV respectively, from a conventional 225 kV X-ray source. Viability assays performed after pre-exposure to 10 μM of IUdR for 48h suggest that complex lethal damage is generated after low energy photons irradiation compared to 137Cs irradiation (662KeV). To further decipher the molecular mechanisms leading to IUdR-mediated radiosensitization, we analyzed the content of DNA damage-induced foci in two glioblastoma cell lines and showed that the decrease in survival under these conditions was correlated with an increase in the content of DNA damage-induced foci in cell lines. Moreover, the follow-up of repair kinetics of the induced double-strand breaks showed the maximum delay in cells labeled with IUdR and exposed to X-ray irradiation. Thus, there appears to be a direct relationship between the reduction of radiation survival parameters and the production of DNA damage with impaired repair of these breaks. These results further support the clinical potential use of a halogenated pyrimidine analog combined with low-energy X-ray therapy.
Collapse
Affiliation(s)
- Emilie Bayart
- INSERM U1030, Gustave Roussy, Université Paris-Saclay, Villejuif, France
- * E-mail:
| | - Frédéric Pouzoulet
- Plateforme de Radiothérapie Expérimentale, Département de Recherche Translationnelle, Institut Curie, Orsay, France
| | - Lucie Calmels
- Département de Radiothérapie, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Jonathan Dadoun
- Département de Radiothérapie, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Fabien Allot
- Département de Radiothérapie, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Johann Plagnard
- CEA, DRT/LIST, Laboratoire National Henri Becquerel, Gif-sur-Yvette cedex, France
| | - Jean-Luc Ravanat
- Laboratoire des Lésions des Acides Nucléiques, Univ. Grenoble Alpes, INAC-SCIB, Grenoble, France; CEA, INAC-SCIB, Grenoble, France
| | - André Bridier
- Département de Radiothérapie, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Marc Denozière
- CEA, DRT/LIST, Laboratoire National Henri Becquerel, Gif-sur-Yvette cedex, France
| | - Jean Bourhis
- Department of Oncology, Radiation Oncology Service, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
| | - Eric Deutsch
- INSERM U1030, Gustave Roussy, Université Paris-Saclay, Villejuif, France
- Faculté de médecine du Kremlin Bicêtre, Université Paris-Saclay, Kremlin Bicêtre, France
| |
Collapse
|
3
|
Alvarez D, Hogstrom KR, Brown TAD, Ii KLM, Dugas JP, Ham K, Varnes ME. Impact of IUdR on Rat 9L glioma cell survival for 25-35 keV photon-activated auger electron therapy. Radiat Res 2015; 182:607-17. [PMID: 25409122 DOI: 10.1667/rr13841.1] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
The goal of the current study was to measure the energy dependence of survival of rat 9L glioma cells labeled with iododeoxyuridine (IUdR) that underwent photon-activated Auger electron therapy using 25-35 keV monochromatic X rays, i.e., above and below the K-edge energy of iodine. Rat 9L glioma cells were selected because of their radioresistance, ability to be implanted for future in vivo studies and analogy to radioresistant human gliomas. Survival curves were measured for a 4 MV X-ray beam and synchrotron produced monochromatic 35, 30 and 25 keV X-ray beams. IUdR was incorporated into the DNA at levels of 0, 9 and 18% thymidine replacement for 4 MV and 35 keV and 0 and 18% thymidine replacement for 30 and 25 keV. For 10 combinations of beam energy and thymidine replacement, 62 data sets (3-13 per combination) provided 776 data points (47-148 per combination). Survival versus dose data taken for the same combination, but on different days, were merged by including the zero-dose points in the nonlinear, chi-squared data fitting using the linear-quadratic model and letting the best estimate to the zero-dose plating efficiency for each of the different days be a fitting parameter. When comparing two survival curves, the ratio of doses resulting in 10% survival gave sensitization enhancement ratios (SER10) from which contributions due to linear energy transfer (LET) (SER10,LET), IUdR radiosensitization (SER10,RS), the Auger effect (SER10,AE) and the total of all effects (SER10,T) were determined. At 4 MV and 35, 30 and 25 keV, SER10,LET values were 1.00, 1.08 ± 0.03, 1.22 ± 0.02 and 1.37 ± 0.02, respectively. At 4 MV SER10,RS values for 9 and 18% IUdR were 1.28 ± 0.02 and 1.40 ± 0.02, respectively. Assuming LET effects were independent of percentage IUdR and radiosensitization effects were independent of energy, SER10,AE values for 18% IUdR at 35, 30 and 25 keV were 1.35 ± 0.05, 1.06 ± 0.03 and 0.98 ± 0.03, respectively. The value for 9% IUdR at 35 keV was 1.01 ± 0.04. First, we found the radioresistant rat 9L glioma cell line exhibited an SER10 due to the Auger effect of 1.35 at (35 keV, 18% IUdR) and an SER10 due to the radiosensitizing effect of 1.40 at (4 MV, 18% IUdR), both significantly less than values for previously reported cell lines. These low individual values emphasize the benefit of their combined value (SER10 of approximately 1.9) for achieving clinical benefit. Second, as expected, we observed that energies below the K-edge of iodine (25 and 30 keV), for which there are L, M and higher shell photoelectric events creating Auger electrons, show no promise for Auger electron therapy. Third, to proceed with future in vivo studies, additional data from 35-65 keV are needed to determine the optimal X-ray energy for IUdR Auger electron therapy. Only then can there be an answer to the question, how well the energy dependence of in vitro survival data supports the potential for photon-activated Auger electron therapy with IUdR in cancer radiotherapy.
Collapse
Affiliation(s)
- Diane Alvarez
- a Department of Physics and Astronomy, Louisiana State University, Baton Rouge, Louisiana
| | | | | | | | | | | | | |
Collapse
|
4
|
Dugas JP, Varnes ME, Sajo E, Welch CE, Ham K, Hogstrom KR. Dependence of cell survival on iododeoxyuridine concentration in 35-keV photon-activated Auger electron radiotherapy. Int J Radiat Oncol Biol Phys 2011; 79:255-61. [PMID: 20932663 DOI: 10.1016/j.ijrobp.2010.07.023] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2010] [Revised: 07/07/2010] [Accepted: 07/07/2010] [Indexed: 11/20/2022]
Abstract
PURPOSE To measure and compare Chinese hamster ovary cell survival curves using monochromatic 35-keV photons and 4-MV x-rays as a function of concentration of the radiosensitizer iododeoxyuridine (IUdR). METHODS AND MATERIALS IUdR was incorporated into Chinese hamster ovary cell DNA at 16.6 ± 1.9%, 12.0 ± 1.4%, and 9.2 ± 1.3% thymidine replacement. Cells were irradiated from 1 to 8 Gy with 35-keV synchrotron-generated photons and conventional radiotherapy 4-MV x-rays. The effects of the radiation were measured via clonogenic survival assays. Surviving fraction was plotted vs. dose and fit to a linear quadratic model. Sensitization enhancement ratios (SER(10)) were calculated as the ratio of doses required to achieve 10% surviving fraction for cells without and with DNA-incorporated IUdR. RESULTS At 4 MV, SER(10) values were 2.6 ± 0.1, 2.2 ± 0.1, and 1.5 ± 0.1 for 16.6%, 12.0%, and 9.2% thymidine replacement, respectively. At 35 keV, SER(10) values were 4.1 ± 0.2, 3.0 ± 0.1, and 2.0 ± 0.1, respectively, which yielded SER(10) ratios (35 keV:4 MV) of 1.6 ± 0.1, 1.4 ± 0.1, and 1.3 ± 0.1, respectively. CONCLUSIONS SER(10) increases monotonically with percent thymidine replacement by IUdR for both modalities. As compared to 4-MV x-rays, 35-keV photons produce enhanced SER(10) values whose ratios are linear with percent thymidine replacement and assumed to be due to Auger electrons contributing to enhanced dose to DNA. Although this Auger effectiveness factor is less than the radiosensitization factor of IUdR, both could be important for the clinical efficacy of IUdR radiotherapy.
Collapse
Affiliation(s)
- Joseph P Dugas
- Department of Physics and Astronomy, Louisiana State University and Agricultural & Mechanical College, Baton Rouge, LA, USA.
| | | | | | | | | | | |
Collapse
|
5
|
Foray N. Aspects radiobiologiques des traitements anticancéreux par rayonnement synchrotron : bilan et perspectives. Cancer Radiother 2010; 14:145-54. [DOI: 10.1016/j.canrad.2009.12.002] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2009] [Revised: 11/26/2009] [Accepted: 12/03/2009] [Indexed: 10/19/2022]
|
6
|
Corde S, Joubert A, Adam JF, Charvet AM, Le Bas JF, Estève F, Elleaume H, Balosso J. Synchrotron radiation-based experimental determination of the optimal energy for cell radiotoxicity enhancement following photoelectric effect on stable iodinated compounds. Br J Cancer 2004; 91:544-51. [PMID: 15266326 PMCID: PMC2409846 DOI: 10.1038/sj.bjc.6601951] [Citation(s) in RCA: 92] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
Abstract
This study was designed to experimentally evaluate the optimal X-ray energy for increasing the radiation energy absorbed in tumours loaded with iodinated compounds, using the photoelectric effect. SQ20B human cells were irradiated with synchrotron monochromatic beam tuned at 32.8, 33.5, 50 and 70 keV. Two cell treatments were compared to the control: cells suspended in 10 mg ml−1 of iodine radiological contrast agent or cells pre-exposed with 10 μM of iodo-desoxyuridine (IUdR) for 48 h. Our radiobiological end point was clonogenic cell survival. Cells irradiated with both iodine compounds exhibited a radiation sensitisation enhancement. Moreover, it was energy dependent, with a maximum at 50 keV. At this energy, the sensitisation calculated at 10% survival was equal to 2.03 for cells suspended in iodinated contrast agent and 2.60 for IUdR. Cells pretreated with IUdR had higher sensitisation factors over the energy range than for those suspended in iodine contrast agent. Also, their survival curves presented no shoulder, suggesting complex lethal damages from Auger electrons. Our results confirm the existence of the 50 keV energy optimum for a binary therapeutic irradiation based on the presence of stable iodine in tumours and an external irradiation. Monochromatic synchrotron radiotherapy concept is hence proposed for increasing the differential effect between healthy and cancerous tissue irradiation.
Collapse
Affiliation(s)
- S Corde
- INSERM U647 ‘Rayonnement Synchrotron et Recherche Médicale’, Université Joseph Fourier & ID17 Biomedical Beamline of European Synchrotron Radiation Facility, CHU A Michallon, BP 217, 38043 Grenoble Cedex 09, France
| | - A Joubert
- INSERM U647 ‘Rayonnement Synchrotron et Recherche Médicale’, Université Joseph Fourier & ID17 Biomedical Beamline of European Synchrotron Radiation Facility, CHU A Michallon, BP 217, 38043 Grenoble Cedex 09, France
| | - J F Adam
- INSERM U647 ‘Rayonnement Synchrotron et Recherche Médicale’, Université Joseph Fourier & ID17 Biomedical Beamline of European Synchrotron Radiation Facility, CHU A Michallon, BP 217, 38043 Grenoble Cedex 09, France
| | - A M Charvet
- INSERM U647 ‘Rayonnement Synchrotron et Recherche Médicale’, Université Joseph Fourier & ID17 Biomedical Beamline of European Synchrotron Radiation Facility, CHU A Michallon, BP 217, 38043 Grenoble Cedex 09, France
| | - J F Le Bas
- INSERM U647 ‘Rayonnement Synchrotron et Recherche Médicale’, Université Joseph Fourier & ID17 Biomedical Beamline of European Synchrotron Radiation Facility, CHU A Michallon, BP 217, 38043 Grenoble Cedex 09, France
- Unité IRM, service de Neuroradiologie, CHU A Michallon, BP 217, 38043 Grenoble Cedex 09, France
| | - F Estève
- INSERM U647 ‘Rayonnement Synchrotron et Recherche Médicale’, Université Joseph Fourier & ID17 Biomedical Beamline of European Synchrotron Radiation Facility, CHU A Michallon, BP 217, 38043 Grenoble Cedex 09, France
- Unité IRM, service de Neuroradiologie, CHU A Michallon, BP 217, 38043 Grenoble Cedex 09, France
| | - H Elleaume
- INSERM U647 ‘Rayonnement Synchrotron et Recherche Médicale’, Université Joseph Fourier & ID17 Biomedical Beamline of European Synchrotron Radiation Facility, CHU A Michallon, BP 217, 38043 Grenoble Cedex 09, France
- IFR no. 1 ‘RMN biomédicale, de la cellule à l'homme’, CHU A Michallon, BP 217, 38043 Grenoble Cedex 09, France
| | - J Balosso
- INSERM U647 ‘Rayonnement Synchrotron et Recherche Médicale’, Université Joseph Fourier & ID17 Biomedical Beamline of European Synchrotron Radiation Facility, CHU A Michallon, BP 217, 38043 Grenoble Cedex 09, France
- Département de Cancérologie et d'Hématologie, Service de Radiothérapie, CHU A Michallon, BP 217, 38043 Grenoble Cedex 09, France
- INSERM U647 ‘Rayonnement Synchrotron et Recherche Médicale’, Université Joseph Fourier & ID17 Biomedical Beamline of European Synchrotron Radiation Facility, CHU A Michallon, BP 217, 38043 Grenoble Cedex 09, France. E-mail:
| |
Collapse
|
7
|
Hallahan DE, Qu S, Geng L, Cmelak A, Chakravarthy A, Martin W, Scarfone C, Giorgio T. Radiation-mediated control of drug delivery. Am J Clin Oncol 2001; 24:473-80. [PMID: 11586099 DOI: 10.1097/00000421-200110000-00012] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Clinical trials of radiotherapy to control drug delivery were initiated in 1999 at Vanderbilt University. The initial studies exploited the findings that platelets are activated in tumor blood vessels after high-dose irradiation as used in radiosurgery and high-dose-rate brachytherapy. Platelets labeled with 111In showed binding in tumor blood vessels. However, the platelet labeling process caused platelets to also accumulate in the spleen. That clinical trial was closed, and subsequent clinical trials targeted protein activation in irradiated tumor blood vessels. Preclinical studies showed that peptide libraries that bind within irradiated tumor blood vessels contained the peptide sequence Arg-Gln-Asp (RGD). RGD binds to integrin receptors (e.g., receptors for fibrinogen, fibronectin, and vitronectin). We found that the fibrinogen receptor (GPIIb/IIIa, alpha2bbeta3) is activated within irradiated tumor blood vessels. RGD peptidemimetics currently in clinical trials include GPIIb/IIIa antagonists and the platelet-imaging agent biapcitide. Biapcitide is an RGD mimetic that is labeled with 99Tc to allow gamma camera imaging of the biodistribution of the GPIIb/IIIa receptor in neoplasms of patients treated with radiosurgery. This study has shown that the schedule of administration of the RGD mimetic is crucial. The peptide mimetic must be administered immediately before irradiation, whereas the natural ligands to the receptor compete for biapcitide binding if biapcitide is administered after irradiation. The authors currently are conducting a dose deescalation study to determine the threshold dosage required for RGD mimetic binding to radiation activated receptor. Radiation-guided clinical trials have been initiated by use of high-dose-rate brachytherapy. In a separate trial, the pharmacokinetics of radiation-inducible gene therapy are being investigated. In this trial, the radiation-activated promoter Egr-1 regulates expression of the tumor necrosis factor alpha gene, which is administered by use of the attenuated adenovirus vector. The Ad.Egr-TNF (ADGV) gene is administered by intratumoral injection of vector followed by irradiation in patients with soft-tissue sarcomas. This review highlights recent findings in these phase I pharmacokinetic studies of radiation-controlled drug delivery systems.
Collapse
Affiliation(s)
- D E Hallahan
- Department of Radiation Oncology, Vanderbilt University, Nashville, Tennessee, USA
| | | | | | | | | | | | | | | |
Collapse
|
8
|
Shinohara K, Nakano H, Ohara H. Detection of Auger enhancement induced in HeLa cells labeled with iododeoxyuridine and irradiated with 150 kV x-rays--Effects of cysteamine and dimethylsulfoxide. Acta Oncol 1996; 35:869-75. [PMID: 9004765 DOI: 10.3109/02841869609104039] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
We examined the effects of cysteamine and dimethylsulfoxide on the lethality of iododeoxyuridine-labeled HeLa cells irradiated with 150 kV x-rays (effective energy was 48 keV) and compared with those irradiated with 60Co gamma-rays. The protectable fraction was estimated from the regression lines for the reciprocal plots of the concentration of protectors, versus the degree of protection. The protectable fraction by cysteamine was 9.4% lower in iododeoxyuridine-labeled cells than in control cells when they were irradiated with x-rays, whereas no such difference was observed with dimethylsulfoxide. The slopes of the regression lines were steeper (i.e., more difficult to protect) for both protectors in iododeoxyuridine-labeled cells irradiated with x-rays. No such differences were observed in gamma-irradiated cells. The cause for these differences are attributable to Auger enhancement. The results suggest that at least a portion of Auger enhancement is not protectable by cysteamine and is hard to be protected by both protectors cysteamine and dimethylsulfoxide.
Collapse
Affiliation(s)
- K Shinohara
- Department of Radiation Research, Tokyo Metropolitan Institute of Medical Science, Bunkyo-ku, Japan.
| | | | | |
Collapse
|
9
|
|
10
|
Relative Sensitivities of Tumors to Brachytherapy. ACTA ACUST UNITED AC 1992. [DOI: 10.1016/b978-0-12-035415-3.50008-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register]
|
11
|
Tishler RB, Geard CR. Correlation of sensitizer enhancement ratio with bromodeoxyuridine concentration and exposure time in human cervical carcinoma cells treated with low dose rate irradiation. Int J Radiat Oncol Biol Phys 1992; 22:495-8. [PMID: 1735686 DOI: 10.1016/0360-3016(92)90861-b] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
The effect of a range of bromodeoxyuridine concentrations and exposure times on the sensitizer enhancement ratio of two human cervical carcinoma cell lines treated with low rate irradiation was evaluated. Both cell lines show a linear, though different, dose response to low dose rate irradiation at dose rates up to 0.62 Gy/hr. Cells were pre-incubated with 0, 1, 5, or 10 microM bromodeoxyuridine for 0, 24, or 48 hr prior to low dose rate irradiation. Based on the survival of cells exposed to 4 Gy, delivered at 0.62 Gy/hr, a slope was determined for an exponential survival curve for each bromodeoxyuridine concentration and exposure time. Sensitizer enhancement ratios were calculated as the ratio of the slopes of the treated and untreated cells from a particular exposure time. Ratios increased linearly initially with a plateauing at higher levels with respect to the product of bromodeoxyuridine concentration and time of exposure for both cell lines with similar degrees of enhancement. A linear relationship has been noted previously for acute irradiation of hamster cells over a similar range of sensitizer concentrations and exposure times. At the highest dose-time points (540 microM-hr) ratios of greater than 2 were attained, which were comparable to results obtained following acute radiation exposures of V-79 cells. These results demonstrate that significant sensitizer enhancement ratios with low dose irradiation can be obtained in human tumor cells after exposures of 2 to 3 doubling times using relatively low concentrations of sensitizer.
Collapse
Affiliation(s)
- R B Tishler
- Department of Radiation Oncology, College of Physicians and Surgeons, Columbia University, NY, NY 10032
| | | |
Collapse
|
12
|
Tishler RB, Geard CR. Low dose rate irradiation and halogenated pyrimidine effects on human cervical carcinoma cells. Int J Radiat Oncol Biol Phys 1991; 21:975-82. [PMID: 1917628 DOI: 10.1016/0360-3016(91)90738-p] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
The response of two human cervical carcinoma cell lines to the combination of bromodeoxyuridine (BrdUrd) incorporation and low dose rate irradiation (LDRI) was assessed. Survival curves were generated following both acute (67.2 Gy/hr) and low dose rate (0.11-0.62 Gy/hr) 137Cs gamma-ray irradiation. The two cell lines exhibited markedly different radiation responses, but for the chronic irradiation, there was no significant difference in response between the low dose rates for either cell line. In all cases, the low dose rate radiation response could be described using a single exponential y = e-alpha D. The sensitizer enhancement ratio (SER) at 10% survival was determined and for the first cell line the low dose rate slope (alpha) was approximately 0.7 Gy-1 with an SER of 1.3-1.5 and an SER of approximately 1.6 for the acute response. In contrast, the second cell line had a low dose rate slope (alpha) of approximately 0.4 Gy-1, an SER of 1.3-1.5, and an SER of approximately 1.7 for the acute response. The similarity of the SER's is notable in light of the marked differences between the intrinsic radiation response of the cells. As the concentration and/or time of exposure to BrdUrd increased, both cytotoxicity and the degree of sensitization also increased. This study demonstrates that SER's with BrdUrd and LDRI are comparable to those obtained for acute exposures in two cervical carcinoma cell lines. The results suggest that this combination of modalities may have clinical applications.
Collapse
Affiliation(s)
- R B Tishler
- Department of Radiation Oncology, Columbia University, New York, NY 10032
| | | |
Collapse
|
13
|
Yabuki H, Nath R. A method for determination of iododeoxyuridine substitution of thymidine using reversed-phase high-performance liquid chromatography. Cell Prolif 1991; 24:33-47. [PMID: 2009316 DOI: 10.1111/j.1365-2184.1991.tb01509.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
An assay for thymidine substitution by iododeoxyuridine (IdUrd) using reversed-phase high-performance liquid chromatography (HPLC) has been developed. Three principal steps in this procedure are: extraction of DNA from cell or tissues, hydrolysis of DNA into deoxynucleosides and separation using HPLC. Approximately 1 microgram of DNA was recovered from 10(5) cells by phenol extraction, and subjected to hydrolysis into deoxynucleosides which required a three-stage DNA digestion using enzymes DNAse I. phosphodiesterase I and alkaline phosphatase. The deoxynucleosides were separated on the Microsorb C18 column with isocratic elution; 90-100% of the DNA was recovered as deoxynucleosides on the column. The method was used to determine quantitatively the percent IdUrd substitution of thymidine in Chinese hamster lung cells in vitro and BA1112 rhabdomyosarcoma in WAG/Rij rats perfused with IdUrd. It was possible to determine the thymidine substitution by IdUrd as small as 1% using a few micrograms of DNA. The close correspondence between the percent substitutions determined by HPLC and those determined by radioactive assay using [125I]-labelled IdUrd, confirmed the accuracy of our HPLC method. The HPLC analysis is especially suitable for the determination of percent IdUrd substitution of thymidine in tissue biopsies from animals used in in vivo experiments or humans undergoing radiation treatment.
Collapse
Affiliation(s)
- H Yabuki
- Yale University School of Medicine, Department of Therapeutic Radiology, New Haven, CT 06510
| | | |
Collapse
|
14
|
Nath R, Bongiorni P, Rossi PI, Rockwell S. Enhanced IUdR radiosensitization by 241Am photons relative to 226Ra and 125I photons at 0.72 Gy/hr. Int J Radiat Oncol Biol Phys 1990; 18:1377-85. [PMID: 2370187 DOI: 10.1016/0360-3016(90)90311-7] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
The dependence of IUdR radiosensitization on photon energy was investigated by irradiating Chinese hamster cells in vitro under aerobic conditions at a dose rate of 0.72 Gy/hr which is typical of temporary brachytherapy implants. It had been observed previously that the IUdR radiosensitization with the 60 keV photons from 241Am is about 1.5 times greater than that with 830 keV (average) photons from 226Ra. It was hypothesized that the enhanced IUdR radiosensitization for 60 keV photons was a result of a larger production of Auger electron cascades from the filling of K-shell vacancies in the iodine atoms, which have a K-shell binding energy of 33.2 keV. Since most of the photons from a 125I source have energies below 33.2 keV, it would be expected that IUdR radiosensitization with 28 keV (average) photons from 125I and 830 keV (average) photons from 226Ra would both be smaller than the radiosensitization with the 60 keV photons from 241Am. To test this hypothesis we compared IUdR radiosensitization for 226Ra, 241Am, and 125I at 0.72 Gy/hr, using Chinese hamster lung cells in vitro. The measured survival curves led to RBEs of 1.20 +/- 0.10 and 1.30 +/- 0.11 for 241Am and 125I photons relative to 226Ra; to IUdR radiosensitization factors at a 10(-5) M concentration of 1.35 +/- 0.11, 1.67 +/- 0.09, and 1.47 +/- 0.08 for 226Ra, 241Am, and 125I, respectively; and to radiosensitization factors at a 10(-4) M concentration of 1.89 +/- 0.16, 3.04 +/- 0.13, and 2.48 +/- 0.17 for 226Ra, 241Am, and 125I, respectively. These results indicate that IUdR produces significant radiosensitization with all three isotopes (226Ra, 241Am, and 125I) for continuous low dose rate irradiations at 0.72 Gy/hr. Also, we observed greater radiosensitization with 241Am photons compared to 226Ra on the higher energy side and to 125I on the lower energy side. These findings support the concept that photon-induced Auger electrons produce a significant increase in IUdR radiosensitization when photons with energies just above the K-edge of the iodine atom are employed for continuous low dose rate irradiations. These findings suggest that regimens combining IUdR infusion with temporary brachytherapy implants using low energy photons in relatively quiescent sites such as brain tumors may have clinical potential, and indicate the need for rigorous preclinical evaluation of this approach.
Collapse
Affiliation(s)
- R Nath
- Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT 06510
| | | | | | | |
Collapse
|
15
|
Martin RF, Murray V, D'Cunha G, Pardee M, Kampouris E, Haigh A, Kelly DP, Hodgson GS. Radiation sensitization by an iodine-labelled DNA ligand. Int J Radiat Biol 1990; 57:939-46. [PMID: 1692580 DOI: 10.1080/09553009014551061] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
An iodinated DNA ligand, iodo Hoechst 33258, which binds in the minor groove of DNA, enhances DNA strand breakage and cell killing by UV-A irradiation. The sites of UV-induced strand breaks reflect the known sequence specificity of the ligand.
Collapse
Affiliation(s)
- R F Martin
- Molecular Sciences Group, Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia
| | | | | | | | | | | | | | | |
Collapse
|
16
|
Leibel SA, Gutin PH, Wara WM, Silver PS, Larson DA, Edwards MS, Lamb SA, Ham B, Weaver KA, Barnett C. Survival and quality of life after interstitial implantation of removable high-activity iodine-125 sources for the treatment of patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 1989; 17:1129-39. [PMID: 2557303 DOI: 10.1016/0360-3016(89)90518-x] [Citation(s) in RCA: 166] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Between January 1980 and January 1988, 95 evaluable patients with recurrent, unifocal, supratentorial malignant gliomas were reirradiated with high-activity iodine-125 sources implanted directly into tumor in afterloaded, removable catheters using computerized tomography-directed stereotaxy. A tumor dose of 5270-15,000 cGy was delivered at a maximum distance of 0.5 cm from the rim of the contrast-enhancing mass seen on CT scans. The median survival for the 50 patients with anaplastic astrocytoma was 81 weeks and for 45 patients with glioblastoma multiforme it was 54 weeks. The 18- and 36-month survival rates for patients with anaplastic astrocytoma were 46% and 28%, respectively; the 18- and 36-month survival rates for patients with glioblastoma multiforme were 22% and 8%, respectively. Because of clinical deterioration, increasing steroid dependency, and increasing mass effect at the implantation site seen on CT scans, necrotic tissue was excised from 47 patients (49%) at craniotomy; in some patients, tumor was mixed with necrotic tissue. The survival of reoperated patients was significantly longer compared with patients who did not undergo this procedure. Serial determination of the Karnofsky Performance Score (KPS) showed that there was no significant deterioration for the group as a whole during the 6 months immediately after implantation. At 18 months, 33 of the patients were alive; KPS ranged between 50 to 90 (mean 79) and 67% were steroid dependent. At 36 months, 18 patients were alive; 17 patients were evaluable with KPS that ranged between 40 to 90 (mean 76) and 53% were steroid dependent. Eleven of the 17 evaluable long-term survivors had a KPS of 80 or higher with a mean of 87. Interstitial brachytherapy may provide long-term survival in selected patients with recurrent malignant gliomas who have been irradiated previously with conventional teletherapy. The quality of life in the majority of long-term survivors appears to be quite satisfactory. Further attempts to control tumor growth using this modality appear to be warranted.
Collapse
Affiliation(s)
- S A Leibel
- Department of Radiation Oncology, School of Medicine, University of California, San Francisco 94143
| | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Humm JL, Charlton DE. A new calculational method to assess the therapeutic potential of Auger electron emission. Int J Radiat Oncol Biol Phys 1989; 17:351-60. [PMID: 2753759 DOI: 10.1016/0360-3016(89)90450-1] [Citation(s) in RCA: 48] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
This paper discusses a new computer code to estimate the efficacy of Auger electron sources in cancer therapy. Auger electron emission accompanies the decay of many radionuclides already commonly used in nuclear medicine, for example; 99mTc and 201Tl. The range of these electrons is in general sub-cellular, therefore, the toxicity of the source depends on the site of decay relative to the genetic material of the cell. Electron track structure methods have been used which enable the study of energy deposition from Auger sources down to the Angstrom level. A figure for the minimum energy required per single strand break is obtained by fitting our energy deposition calculations for 125I decays in a model of the DNA to experimental data on break lengths from 125I labeled plasmid fragments. This method is used to investigate the efficiency of double strand break production by other Auger sources which have potential value for therapy. The high RBE of Auger sources depends critically on the distance between the source and target material. The application of Auger emitters for therapy may necessitate a carrier molecule that can append the source to the DNA. Many DNA localizing agents are known in the field of chemotherapy, some of which could be carrier molecules for Auger sources; the halogenated thymidine precursors are under scrutiny in this field. The activation of Auger cascades in situ by high energy, collimated X ray and neutron beams is also assessed.
Collapse
Affiliation(s)
- J L Humm
- MRC Radiobiology Unit, Chilton, Didcot, Oxon, GB
| | | |
Collapse
|
18
|
|